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The 89-kDa STAT3 protein is a latent transcription
factor which is activated in response to cytokines (in-
terleukin (IL)-5 and -6) and growth factors (epidermal
growth factor). Binding of IL-5 to its specific receptor
activates JAK2 which leads to the tyrosine phosphoryl-
ation of STAT3 proteins. Here we report the cloning of a
cDNA encoding a variant of the transcription factor
STAT3 (named STAT3b) which was isolated by screen-
ing an eosinophil cDNA library. Compared to wild-type
STAT3, STAT3b lacks an internal domain of 50 base
pairs located near the C terminus. This splice product is
a naturally occurring isoform of STAT3 and encodes a
80-kDa protein. We found by reconstitution of the hu-
man IL-5R in COS cells that like STAT3, STAT3b is phos-
phorylated on tyrosine and binds to the pIRE from the
ICAM-1 promoter after IL-5 stimulation. However,
STAT3b fails to activate a pIRE containing promoter in
transient transfection assays. Instead, co-expression of
STAT3b inhibits the transactivation potential of STAT3.
These results suggests that STAT3b functions as a neg-
ative regulator of transcription.
Stimulation of transcription factors by cytokines or growth
factors is an important step in activating specific gene tran-
scription leading to cell growth, differentiation, and many
other cellular functions. To activate or repress transcription,
transcription factors must be located in the nucleus, bind DNA,
and interact with the basal transcriptional machinery. Most of
these processes are achieved by phosphorylation of a transcrip-
tion factor by protein kinases (1, 2). One of the earliest signal-
ing events after cytokine stimulation is the activation of non-
receptor protein tyrosine kinases, such as members of the Src
and Janus kinase (JAK) families (3). Many individual cytokine
receptors are linked to specific members of the JAK family
which are activated after ligand binding. The activated JAK
kinases phosphorylate and activate a novel family of transcrip-
tion factors termed signal transducers and activators of tran-
scription (STATs)1 (4). STAT proteins were first recognized in
the interferon-a (IFN-a) and b signaling pathway. IFNa acti-
vates a latent cytoplasmic transcription factor complex inter-
feron-stimulated gene factor 3 (5–7). This complex consists of a
48-kDa DNA-binding component, and the tyrosine-phosphoryl-
ated proteins STAT1a, STAT1b, and STAT2 (8). By contrast,
only STAT1a is tyrosine phosphorylated upon stimulation of
cells with IFN-g (9). Until now, eight members of the STAT
family: STAT1a, STAT1b (6, 7), STAT2 (6), STAT3 (10, 11),
STAT4 (12, 13), STAT5A, STAT5B (14–16), and STAT6 (17)
have been identified and characterized. All the STATs are
widely expressed in different cell types and tissues, except for
STAT4, which is expressed predominantly in testis and in cells
of hematopoietic origin. Phosphorylation on tyrosine of the
STAT proteins is required for dimerization, DNA-binding, and
the activation of transcription (18, 8). However, STAT1b, which
is a splice product of STAT1a and lacks 38 amino acids of the
carboxyl terminus, is phosphorylated on tyrosine but is tran-
scriptionally inactive (18). Furthermore, we and others found
that H7, which is a serine/threonine kinase inhibitor, blocked
the transactivation potential of STAT1 and/or STAT3 (19–22).
These results suggest that phosphorylation of serine residues
in STAT1 and STAT3 are necessary for the transcriptional
activity of these proteins.
Cytokines such as interleukin-3 (IL-3), IL-5, and granulo-
cyte-macrophage colony stimulating factor (GM-CSF) play an
important role in hematopoiesis (23–25). Although IL-3 and
GM-CSF also have effects on other hematopoietic lineages (25,
26), the actions of IL-5 in humans are restricted to eosinophils
and basophils, since the IL-5 receptor (IL-5R) is only expressed
on these cell types (27, 28). IL-5 is essential for eosinophil
differentiation (29, 30) and plays an important role in function-
ing of mature eosinophils and basophils (31–35). The IL-5R is
composed of a unique a subunit associated with a bc subunit
that is identical to those of the receptors for IL-3 and GM-CSF
(36). We and others have shown that JAK2 is activated by IL-3,
IL-5, and GM-CSF (37, 38), and constitutively associates with
the membrane-proximal region of the bc subunit (39). Recently,
we have described that STAT3 activity increases in response to
interleukin-5 (IL-5) in both BaF3 and COS cells ectopically
expressing the hIL-5 receptor (IL-5R) (40). Although STAT3 is
tyrosine phosphorylated and activated by IL-5 in these cells, it
was only activated to a very low extent in mature eosinophils.
Based on this and the observation that multiple STATs are
activated by IL-5 in eosinophils (37), we screened an eosinophil
cDNA library to identify IL-5 induced novel STAT cDNAs.
Here we report the cloning and characterization of a STAT3
variant which we isolated from the eosinophil cDNA library.
This protein (STAT3b) is a truncated form of STAT3 which is
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probably generated by differential splicing. STAT3 and
STAT3b protein are co-expressed in various cell types. We
found that STAT3b is rapidly phosphorylated on tyrosine upon
IL-5 stimulation of COS cells. However, although STAT3b ef-
ficiently binds to the palindromic IL-6/IFNg response element
(pIRE) from the intercellular adhesion molecule 1 (ICAM-1)
promoter, it is unable to activate a promoter containing this
pIRE element. We also demonstrate that STAT3b is a strong
dominant inhibitor of transcription.
MATERIALS AND METHODS
Eosinophil cDNA Library Construction—Human eosinophils were
isolated from two hyper-eosinophilic individuals according to a slight
modification (41) of the method described previously (42). The purity of
the eosinophils collected was at least 95% as determined by histochem-
ical staining of cytospins with May-Grunwald-Giemsa stain. Viability
determined by trypan blue exclusion was more than 98%. Total RNA
was extracted from 1 3 108 eosinophils using an Rnaid kit according to
the manufacturers instructions (BIO 101 Inc.). Poly(A)1 mRNA was
extracted by oligo(dT) affinity purification using Dynabeads Oligo(dT)25
(Dynal, Norway). This mRNA was used to construct an EcoRI/XhoI
directional cDNA library in the l ZAPII vector as described by the
manufacturer (Stratagene). The library contained greater than 2 3 106
primary recombinants with a background of less than 10%. The average
insert size was approximately 1.5 kilobase and the largest inserts were
estimated to be greater than 5 kilobases.
Cell Culture, Reagents, and Antibodies—Monkey COS-1 cells were
cultured in Dulbecco’s modified Eagle’s medium (Life Technologies,
Inc.) supplemented with 10% heat inactivated fetal calf serum. Human
IL-5 (hIL-5) was a kind gift of Dr. D. Fattah (Glaxo Wellcome, Steven-
age). The anti-phosphotyrosine monoclonal antibody 4G10 was ob-
tained from UBI (Lake Placid, NY). The monoclonal antibody directed
against STAT1a/b was purchased from Transduction Laboratories
(Lexington, KY). The STAT3 rabbit polyclonal antibodies K15 (directed
against amino acids 626–640) and C20 (directed against amino acids
750–769) were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA).
Synthetic Oligonucleotides and Plasmid Construction—Oligonucleo-
tides with the following sequence were used in this study (only the top
strand is shown): the human ICAM-1 pIRE, 59-AGCTTAGGTTTCCGG-
GAAAGCAC-39. The 2xpIREtkluc and pICAM1–339 reporter constructs
has been described by Caldenhoven et al. (43) and the pSV-lacZ expres-
sion vector by Shen et al. (44). pSGhIL5Ra was constructed by inserting
the cDNA for the human IL-5a receptor from pBKhIL5Ra (45) into the
Not/KpnI sites of pSG513. pSGhIL5Rb was constructed by inserting the
cDNA for the human bc subunit from pSV532 (36) into the EcoRI sites
of pSG513. The expression vectors containing the cDNAs for hSTAT1,
mSTAT3, and hSTAT4 were provided by Dr. James E. Darnell, Jr. (7,
11). The hSTAT6 cDNA was provided by Dr. Steven L. McKnight (17).
Full-length STAT cDNAs were used for the screening of the cDNA
library. The hSTAT3 and hSTAT3b were isolated from the eosinophil
cDNA library and cloned into the EcoRI site of PSG513.
Transient Transfections—For transfection experiments, COS cells
were split 1:3 in 6-well plates (Costar), and 2 h later the cells were
transfected with 10–20 mg of supercoiled plasmid DNA by the calcium
phosphate coprecipitation technique (46). Following 16–20 h exposure
to the calcium-phosphate precipitate, medium was refreshed, and cells
were incubated for 16 h with IL-5. Transfected cells were subsequently
harvested for luciferase assay (47) and lacZ determination (48).
Gel Retardation Assay—Nuclear extracts were prepared from un-
stimulated and IL-5 stimulated COS cells following a previously de-
scribed procedure (49). Oligonucleotides were labeled by filling in the
cohesive ends with [a-32P]dCTP using Klenow fragment of DNA polym-
erase I. Gel retardation assays were carried out according to published
procedures with slight modifications (5). Briefly, nuclear extracts (10
mg) were incubated in a final volume of 20 ml, containing 10 mMHEPES,
pH 7.8, 50 mM KCl, 1 mM EDTA, 5 mM MgCl2, 10% (v/v) glycerol, 5 mM
dithiothreitol, 2 mg of poly(dI-dC) (Pharmacia), 20 mg of bovine serum
albumin, and 1.0 ng of 32P-labeled ICAM1-pIRE oligonucleotide for 20
min at room temperature. In competition experiments, extracts were
incubated for 5 min with the indicated molar excess of unlabeled oligo-
nucleotide prior to the addition of labeled oligonucleotide. Supershift
analysis were performed by preincubating 10 mg of nuclear extract with
1 ml (1 mg) of anti-STAT3 antibody for 30 min on ice prior to addition of
the binding buffer and 32P-labeled probe.
Immunoprecipitation and Western Blotting—Unstimulated and IL-5
stimulated COS cells were incubated with RIPA lysis buffer (20 mM
Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium
deoxycholate, 5 mM EDTA, Na3VO4, 10 mg/ml aprotinine, 1 mM phen-
ylmethylsulfonyl fluoride, 1 mM leupeptin) for 15 min on ice. The lysate
was centrifuged to remove DNA and cellular debris. The cell lysates
were incubated with the anti-STAT3 polyclonal antibody for 1 h at 4 °C.
Immune complexes were then precipitated with protein A-Sepharose
for 1 h at 4 °C, washed three times with lysis buffer, and boiled in 1 3
Laemmli’s sample buffer. The proteins were electrophoresed on a SDS-
polyacrylamide gel and transferred to nitrocellulose membrane. After
blocking in TBST (150 mM NaCl, 10 mM Tris, pH 8.0, 0.3% Tween 20)
with 5% bovine serum albumin, the membrane was either incubated
with the anti-phosphotyrosine (4G10) monoclonal antibody, or with the
polyclonal anti-STAT3 antibody. After washing three times with TBST
the membrane was incubated for 1 h with peroxidase-conjugated rabbit
anti-mouse or swine anti-rabbit antibodies, respectively. In both cases
the membrane was washed five times with TBST and immunoprecipi-
tated proteins were visualized with enhanced chemiluminescence
(ECL, Amersham). Between the incubation with 4G10 and STAT3
antibodies the membrane was stripped with 1% SDS, 30 mM Tris, pH
8.0, 50 mM b-mercaptoethanol for 2 3 15 min at 55 °C.
RESULTS
Isolation of a Short Form of STAT3—In order to identify new
STAT proteins expressed in eosinophils that may play a role in
IL-5 signaling, an eosinophil cDNA library was screened with a
labeled probe containing the full-length STAT cDNAs of
hSTAT1, mSTAT3, hSTAT4, and hSTAT6. After low stringency
screening of the cDNA library, several positive phage clones
were isolated. The inserts of these clones were characterized by
Southern hybridization and sequencing. All the isolated clones
encode known STAT proteins including hSTAT3, hSTAT4, and
hSTAT6. However, one of the STAT3 positive cDNA clones
showed a different restriction pattern compared to the wild
type STAT3 cDNA. Sequencing of this clone revealed that it is
almost identical to STAT3 but lacks an internal part of 50 base
pairs, covering nucleotides 2145–2195 near the COOH termi-
nus (Fig. 1A). This deletion removes codons 716 to 732 and in
addition causes a shift in the open reading frame resulting in
the formation of a stop codon after 7 amino acids (Fig. 1B). This
truncated STAT3 mRNA encodes a protein consisting of the
first 715 amino acids of STAT3 plus an additional 7 unique
amino acids. Comparison of the amino acids in the carboxyl-
terminal region shows that this truncated STAT3 protein con-
tains the tyrosine phosphorylation site at position 704, but
lacks the conserved PMSP sequence which is a substrate for a
serine kinase (50). Based on published work (7) identifying a
splice variant of STAT1 named STAT1b, it is likely that the
truncated form of STAT3 results from an alternative splicing
event as well. We therefore designated the STAT3 clone with
this internal deletion as STAT3b. To determine whether this
isoform is not a cloning artifact we performed a polymerase
chain reaction experiment with internal primers depicted in
Fig. 1A on mRNA from the cell types mentioned below. As
expected, two polymerase chain reaction products were formed
a 300-base pair fragment and a minor 250-base pair fragment
(data not shown). Sequencing revealed that these DNA frag-
ments corresponds to the internal regions of STAT3 (300 base
pairs) and STAT3b (250 base pairs). Additional evidence that
this isoform is not a cloning artifact comes from the independ-
ent isolation of this cDNA by Schaefer et al. (51), who isolated
this cDNA via a two hybrid screen with a N-terminal segment
of c-Jun.
STAT3b Is Expressed in Different Cell Types—To investigate
the existence of the STAT3b protein and to establish its tissue
distribution, we performed a STAT3 immunoprecipitation from
different cell types. For this purpose, cell lysates were prepared
from U937, HL-60, BaF3 cells, eosinophils, COS cells, and COS
cells transfected with the cDNA encoding for STAT3b (COS/
STAT3b). The proteins were precipitated with a specific STAT3
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antibody directed against residues 626–640 and immuno-
blotted with this STAT3 antibody. Fig. 2A shows that untrans-
fected COS cells express only a low amount of the 89-kDa
STAT3 protein. However, overexpressing STAT3b in COS cells
results in the appearance of an 80-kDa protein which comi-
grated with an endogenously expressed 80-kDa protein in the
other cell types analyzed with the STAT3 antibody. The expres-
sion of this 80-kDa protein varies between the different cell
types studied (Fig. 2A). This 80-kDa protein was also found in
blood monocytes, lymphocytes, and neutrophils (data not
shown). To ascertain that the endogenously expressed 80-kDa
protein was STAT3b, we precipitated the proteins with a
STAT3 antibody directed against amino acids 750–769, a do-
main lacking in the STAT3b protein. Using this antibody we
detect only the 89-kDa wild type STAT3 protein in COS/
STAT3, COS/STAT3b, U937, and HL-60 cells (Fig. 2C, lanes
5–8). When proteins from these cells were precipitated with
STAT3 antibodies directed against residues 629–640, two
STAT3 proteins appeared of 89 and 80 kDa, except for the
COS/STAT3 cells which shows only the wild type STAT3 (Fig.
2C, lanes 1–4). We therefore conclude that the endogenously
expressed 80-kDa protein in primary cells as well as in the cell
lines is likely to be STAT3b since it is not recognized by an
antibody against the N terminus which is lacking from
STAT3b.
Tyrosine Phosphorylation and DNA Binding of
STAT3b—We have previously shown that STAT3 becomes ty-
rosine phosphorylated after IL-5 treatment in both BaF3 and
COS cells (40). Since STAT3b still retains the tyrosine residue
necessary for STAT3 activation, we were interested whether
STAT3b is phosphorylated on tyrosine after IL-5 stimulation.
To test this prediction we co-transfected COS cells with expres-
sion vectors encoding both subunits of the IL-5 receptor (IL-
5Ra and IL-5Rb), together with STAT3 or STAT3b. We immu-
FIG. 1. Nucleotide and amino acid sequence of the COOH-
terminal regions of human STAT3 and STAT3b. A, STAT3 and
STAT3b cDNAs were isolated from a human eosinophil cDNA library,
subcloned, and sequenced. As can be observed, STAT3b contains an
internal deletion of 50 nucleotides. The positions of the stop codons used
in STAT3 and STAT3b and the primers used for the detection of STAT3
and STAT3b mRNA are indicated. B, schematic representation of the
amino acid sequences of STAT3 and STAT3b around the internal dele-
tion. Positions of the Src homology 2 (SH2), SH3, and tyrosine phos-
phorylation (Tyr704) domains are indicated. Due to the deletion in
STAT3b, the reading frame is switched and a stop codon is generated 7
amino acids downstream of the internal deletion.
FIG. 2. Expression and tyrosine phosphorylation of the
STAT3b protein. A, whole cell extracts from COS (lane 1), COS trans-
fected with STAT3b (lane 2), BaF3 (lane 3), HL-60 (lane 4), U937 (lane
5), and eosinophils (lane 6) were monitored for the presence of STAT3
and STAT3b by immunoprecipitation with a STAT3 specific antibody
(amino acids 629–640) followed by Western blotting with the same
antibody. The protein of about 89 kDa represents STAT3, while the
smaller protein (80 kDa) is STAT3b. STAT3 and STAT3b are co-ex-
pressed in different cell types, although at different ratios. B, COS cells
were transfected with the IL-5R a and b cDNAs together with the pSG5
expression vector (lanes 1 and 2), STAT3 (lanes 3 and 4), or STAT3b
(lanes 5 and 6). 48 h after transfection, cells received IL-5 for 15 min
(lanes 2, 4, and 6), after which cells were lyzed and STAT3 was immu-
noprecipitated. The blot was first probed with an anti-phosphotyrosine
antibody (upper panel), stripped, and probed with the STAT3 antibody
(lower panel). IL-5 causes a strong increase in tyrosine phosphorylation
of both STAT3 and STAT3b. The faster migrating bands observed in
lanes 3 and 4 (lower panel) are sometimes observed, and are probably
the result of degradation of STAT3. C, whole cell extracts from COS
cells transfected with STAT3 (lanes 1 and 5), or STAT3b (lanes 2 and 6),
U937 (lane 3 and 7), and HL-60 cells (lanes 4 and 8) were immunopre-
cipitated with a STAT3 antibody (629–640) (lanes 1–4) or a STAT3
antibody (amino acids 750–769) (lanes 5–8) and blotted with STAT3
antibody (629–640). The endogenously expressed 80-kDa protein is
likely to be STAT3b.
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noprecipitated STAT3 from unstimulated and IL-5 stimulated
COS cells and tyrosine phosphorylation was then monitored by
Western blotting using the anti-phosphotyrosine antibody
4G10. Fig. 2B shows that both wild-type STAT3 and STAT3b
are phosphorylated on tyrosine after IL-5 stimulation. How-
ever, although the expression of STAT3b protein is less then
wild-type STAT3, the amount of tyrosine phosphorylation is
higher. In addition, even in the absence of IL-5 signaling, we
detected some basal level tyrosine phosphorylation of STAT3b,
which we have never observed with STAT3.
Tyrosine phosphorylation of STAT proteins leads to dimer-
ization, translocation to the nucleus, and binding to specific
binding sites on the DNA. We therefore tested the ability of
STAT3b to bind DNA and compared this with wild-type
STAT3. COS cells expressing the IL-5R and either wild-type
STAT3 or STAT3b were treated with IL-5 for 15 min and
nuclear extracts were prepared. When these nuclear extracts
were assayed in a gel retardation assay for binding to a 32P-
labeled ICAM-1 pIRE, an increase in STAT3 and STAT3b
binding was observed after IL-5 treatment (Fig. 3). Unexpect-
edly, however, the STAT3 complex migrated faster than the
STAT3b complex. The STAT3b complex is specific because an
anti-STAT3 antibody produced a supershift, while STAT1 an-
tiserum had no effect on this complex. Furthermore, the DNA
binding activity of STAT3b is higher than STAT3, which is
probably due to the higher amount of tyrosine-phosphorylated
STAT3b proteins observed (Fig. 2B). In addition, we observed
some basal level DNA binding activity by STAT3b in unstimu-
lated cells, which is in agreement with the observed tyrosine
phosphorylation in unstimulated cells (Fig. 2B). We can con-
clude that both wild-type STAT3 and STAT3b are tyrosine
phosphorylated after IL-5 stimulation which results in an in-
crease in DNA binding of both proteins.
STAT3b Acts as a Dominant Transcriptional Repressor—To
compare the transcriptional activity of STAT3 with STAT3b,
we transiently transfected COS cells with expression vectors
for the IL-5R, wild-type STAT3, or STAT3b together with a
luciferase reporter construct, containing two copies of the pIRE
from the ICAM-1 promoter. Transfection of the wild-type
STAT3 cDNA shows an IL-5 dependent 15-fold increase in
luciferase activity (Fig. 4A). By contrast, transfection of
STAT3b gave almost no increase in luciferase activity after
IL-5 stimulation. An explanation for this could be that the
region which is absent from STAT3b contains a domain impor-
tant for transactivation. We further determined the effect of
FIG. 3. Both STAT3 and STAT3b bind to DNA after activation
by IL-5. The hIL-5 receptor and STAT3 or STAT3b were expressed in
COS cells. These cells were either untreated or treated for 30 min with
IL-5, after which nuclear extracts were prepared. Nuclear extract were
assayed for binding to the 32P-labeled ICAM-1 pIRE in band shift
experiments. For competition experiments, extracts were preincubated
for 5 min with a 50-fold molar excess of unlabeled oligonucleotide as
indicated. For supershift analysis, the extracts were incubated with
either anti-STAT1a or anti-STAT3 antibodies for 30 min before the
addition of the 32P-labeled ICAM-1 pIRE. IL-5 clearly induces binding
of STAT3 and STAT3b to the ICAM-1 pIRE.
FIG. 4. STAT3b is a dominant negative regulator of transcrip-
tion. A, COS cells were transfected with the IL-5R, a pIRE containing
luciferase reporter construct and STAT3 or STAT3b. 24 h post-trans-
fection, cells were stimulated for 16 h with IL-5 (10210 M), after which
transcriptional activation was measured by assaying for luciferase ac-
tivity. Fold induction represents luciferase activity in IL-5-treated cells
compared to untreated cells, and is the mean of three independent
experiments. STAT3b is unable to support IL-5 induced activation of
the pIRE reporter construct. B, COS cells were transfected as described
in A with different amounts of STAT3 and STAT3b as indicated. Low
amounts of STAT3b already significantly decrease trans-activation by
STAT3, while high amounts of STAT3b completely inhibit STAT3-
mediated transcriptional activation. C, COS cells were transfected as
described in A and B. We used the ICAM-1 promoter as a luciferase
reporter construct (pIC-339luc). STAT3b is also transcriptionally inac-
tive on the natural ICAM-1 promoter.
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STAT3b on transactivation mediated by STAT3. We tested this
by co-transfection of an increasing amount of STAT3b expres-
sion vector together with a constant amount of STAT3 expres-
sion vector. The total amount of DNA was kept constant by
adding the pSG5 vector. In this experiment we see that trans-
activation by STAT3 is already inhibited by low amounts of
STAT3b (Fig. 4B). Western blotting indicated that STAT3b
expression did not alter the level of STAT3 (data not shown).
These results implicate that STAT3b can act as a dominant
negative regulator of STAT3-mediated transcription. To make
sure that this dominant effect of STAT3b also occurs on a
natural promoter we used the ICAM-1 promoter containing the
IRE in transient transfections experiments. COS cells were
transfected with this reporter construct together with STAT3,
STAT3b, or a combination of both STAT proteins and stimu-
lated with IL-5. We found that although STAT3 is an activator
of the ICAM-I promoter, STAT3b is transcriptionally inactive
on the ICAM-1 promoter and acts as a dominant negative
regulator of STAT3-mediated transcription. (Fig. 4C).
Since all STAT proteins form homo- or heterodimers after
phosphorylation on tyrosine, a mechanism for the inhibition
could be that STAT3 and STAT3b form heterodimers which are
unable or less able to mediate transactivation. To investigate
this, we prepared nuclear extracts from IL-5-treated COS cells
transfected with STAT3 and increasing amounts of STAT3b.
We assayed these nuclear extracts for binding to the ICAM-1
pIRE and performed a long run gel retardation to resolve the
different complexes. As we already observed, the affinity of
STAT3b homodimers (Fig. 5A, lane 6) to the pIRE is higher
then the binding of STAT3 homodimers (lane 1). Interestingly,
an intermediate complex C2 was observed when STAT3b is
co-transfected together with STAT3, which is likely to consist
of a STAT3/STAT3b heterodimer. To resolve all three DNA-
binding complexes, lanes 2–7 were exposed less than lane 1. We
also identified the components in these complexes using two
specific STAT3 antibodies, one directed against residues 629–
640 supershifting both STAT3 and STAT3b (Fig. 5B, lanes 2
and 5), the other against residues 750–769 which recognized
only STAT3 (lanes 3 and 6). We further show that the STAT3
(750–769) antibody which recognizes only STAT3 supershifted
only the STAT3/STAT3b heterodimer and had no effect on the
STAT3b homodimer (lane 9). These results clearly demonstrate
that STAT3 and STAT3b form heterodimeric DNA-binding
complexes.
DISCUSSION
STAT proteins are a rapidly expanding family of transcrip-
tion factors that transduce short-term cytoplasmic signals elic-
ited by polypeptide growth factors and cytokines into long-term
changes in gene expression (52). Here, the cloning and charac-
terization of a novel isoform of the STAT3 transcription factor
is reported, which is named STAT3b in analogy with STAT1a/
STAT1b. Although STAT3b is phosphorylated on tyrosine upon
IL-5 stimulation and binds efficiently to the pIRE from the
ICAM-1 promoter, it fails to support pIRE-driven transcription
in IL-5-stimulated cells. Moreover, STAT3b is an efficient dom-
inant negative regulator of STAT3-mediated transcription.
Differential splicing in the STAT family is not unprece-
dented. Schindler et al. (7) have shown that the STAT1 gene
encodes at least two different proteins, STAT1a and STAT1b,
that are generated by alternative splicing. Like STAT3b,
STAT1b can be phosphorylated on tyrosine but fails to activate
transcription (18). However, whether STAT1b can act as a
dominant negative regulator of STAT1a was never investi-
gated. The splicing event occurs at a highly homologous posi-
tion in STAT1 and STAT3 (22, 52), suggesting that STAT1 and
STAT3 might have a conserved exonic organization as was
previously demonstrated for STAT1 and STAT2 (53). Verifica-
tion of this hypothesis, however, awaits deciphering of the
precise exonic structure of the STAT3 gene.
It was previously suggested that besides tyrosine phospho-
rylation, serine phosphorylation might play a crucial role in
gene regulation by STAT proteins. The serine/threonine kinase
inhibitor H7 was shown to be able to block transcriptional
regulation by STAT1 and STAT3 (19, 20). Similarly, Boulton et
al. (22) reported an H-7 sensitive phosphorylation of STAT3,
but not STAT1. In addition, it was shown that serine phospho-
rylation might be necessary for DNA binding by STAT3 ho-
modimers, but not by STAT1 homo- or STAT1/STAT3 het-
erodimers (21). In this paper we have shown that STAT3b is
efficiently phosphorylated on tyrosine upon IL-5 stimulation
(Fig. 2B), which leads to a strong increase in DNA binding by
STAT3b (Fig. 3). However, in contrast to STAT3, STAT3b is
unable to mediate transactivation via a pIRE containing pro-
moter. Examination of the amino acids deleted from STAT3b
shows the presence of a large number of serine and threonine
residues, of which serine 727 is conserved between STAT1a,
STAT3, STAT4, and STAT5, but not STAT1b. Interestingly,
this serine lies within a highly conserved PMSP sequence that
was previously shown to be a microtubule-associated protein
FIG. 5. Heterodimerization between STAT3 and STAT3b. A,
COS cells were transfected with the IL-5R and different amounts of
STAT3 and STAT3b. 48 h after transfection, cells were treated with
IL-5 for 15 min and DNA binding activity was monitored using a
32P-labeled pIRE. Co-expression of STAT3 (C3) and STAT3b (C1) re-
sults in the formation of a heterodimeric complex (C2). B, nuclear
extracts from COS cells transfected with STAT3, STAT3b, or STAT3/
STAT3b, stimulated for 15 min with IL-5 were preincubated with two
different STAT3 antibodies STAT3 Ab (629–640) and STAT3 Ab (750–
769). DNA binding activity was monitored using a 32P-pIRE. These data
clearly show the formation of STAT3b homodimers and STAT3/STAT3b
heterodimers.
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kinase recognition sequence (50). The importance of this serine
was very recently shown by Wen et al. (20), who showed that
this serine is inducibly phosphorylated in both STAT1a and
STAT3. Furthermore, when they mutated this serine to ala-
nine (STAT1aS), trans-activation was decreased 5-fold, al-
though STAT1aS was still able to support an IFNg-induced
5-fold increase in transcription, whereas STAT1b is completely
inactive in this system (20). Similarly, mutation of serine 727
in STAT3 also decreased transactivation about 2.5-fold, al-
though the mutant was still able to support an 8-fold induction
of INFg activation site-mediated transcription (20). The lack of
serine 727 in STAT3b explains some, but not all of the results
presented in this paper. STAT3b is completely unable to me-
diate transcriptional activation in COS cells (Fig. 4A), whereas
STAT3 with the 727 mutation is still a relatively good trans-
activator in U3A cells (20). This might be caused by cell type-
specific differences between COS and U3A. Alternatively, there
might be more phosphorylated residues present in the region
that is deleted from STAT3b which contribute to transcrip-
tional activation. Finally, the basal level tyrosine phosphoryl-
ation (Fig. 2B) and DNA binding (Fig. 3) observed with STAT3b
in unstimulated COS cells represents a striking difference with
both STAT3–727 and STAT1b. Although we do not have any
experimental data to support this hypothesis, this observation
suggests the presence of a domain in the COOH-terminal 55
amino acids of STAT3 that is somehow able to block STAT3
phosphorylation by JAK kinases in unstimulated cells.
The observation that STAT3b is transcriptionally inactive is
in contrast with data published recently by Schaefer et al. (51).
They have identified STAT3b via a two-hybrid system as a
protein capable of binding to the NH2-terminal part of the
c-Jun protein. Furthermore, they have shown that STAT3b is
transcriptionally active on the a2-macroglobulin promoter in
the absence of added cytokines. This constitutive transactiva-
tion potential is consistent with our own results showing a
constitutive tyrosine phosphorylation of STAT3b. The opposite
effects found on the transactivation potential of STAT3b can be
due to the promoter targets used in both studies. We have used
an artificial reporter containing only STAT binding sites and
the natural ICAM-I promoter, while the a2-macroglobulin pro-
moter used by Schaefer et al. (51) contains a STAT binding site
closely linked to a Jun binding site. Occupation of the Jun
binding site by members of the Jun/Fos family might somehow
alter the transcription activation potential of STAT3b. Oppo-
site effects by a single transcription factor on different promot-
ers has also been described for hormone receptors which can
either activate or repress gene transcription depending on the
promoter (54). Further experiments are required for decipher-
ing the different roles that STAT3b might have in transcrip-
tional regulation.
The observed dominant negative effect of STAT3b over
STAT3 might be caused by two different mechanisms. One
possibility might be that STAT3b homodimers have a higher
affinity for the pIRE, and therefore occupy these sites on the
DNA even when STAT3 is more abundantly expressed. Indeed,
we have observed that while STAT3b expression was 2-fold
lower in transfected COS cells (Fig. 2B), DNA binding by
STAT3b was 2–3-fold higher compared to STAT3 (Fig. 3). This
is likely to be caused by the higher extent of tyrosine phospho-
rylation observed in STAT3b (Fig. 2B). On the other hand,
since dimerization of STAT proteins is required for the forma-
tion of transcriptionally active DNA binding complexes (52),
heterodimerization between STAT3 and STAT3b might be in-
volved in the dominant negative effect. In Fig. 5 we show that
STAT3 and STAT3b indeed form a heterodimer. Moreover,
even a small amount of STAT3b is sufficient to disrupt all the
STAT3 homodimers and drive them into STAT3/STAT3b het-
erodimers. However, at this ratio between STAT3 and STAT3b
(6:2 mg), we still observe transcriptional activation of a pIRE
containing plasmid (Fig. 4B), although it is 50% less compared
to STAT3 alone. This suggests that the STAT3/STAT3b het-
erodimer is able to support IL-5 induced transcription, albeit
with a lower efficiency than the STAT3 homodimer. Taken
together, the observed dominant negative effect of STAT3b is
likely to be caused by a combination of transcriptionally inac-
tive STAT3b homodimers with high DNA binding activity and
STAT3b/STAT3 heterodimers which are weak transcriptional
activators. The generation of transcriptional activators and
repressors from the same gene is not unprecedented (55).
mTFE3, a murine transcription factor involved in the activa-
tion of immunoglobulin heavy chain transcription, is turned
into a repressor by a splicing event that removes part of the
activation domain (56). Similarly, a splicing event removing
part of the activation domain of FosB results in the expression
of DFosB, an inhibitor of Fos/Jun transcriptional activity (57),
while splicing out the activation domains of CREMt generates
CREMa, which, despite the fact that it retains the protein
kinase A phosphoacceptor site, is an efficient antagonist of
cAMP-induced transcription (58, 59). The use of alternative
initiation codons can also be a mechanism to generate activa-
tors and repressors from the same mRNA, as was reported for
liver-enriched activator protein and liver-enriched inhibitory
protein (60) and for CREM and S-CREM (61). In this paper we
report that an alternative splicing event removing 55 amino
acids from the COOH terminus of STAT3 generates STAT3b,
an efficient repressor of STAT3-mediated transcription. Al-
though it is likely that the removal of serine 727 contributes to
this switch from activator to repressor, the precise molecular
mechanism awaits further mutational analysis of STAT3, since
the nature of the activation domain of STAT3 remains to be
elucidated. As was described previously for mTFE3, FosB,
CREM, and liver-enriched activator protein (55), we found that
the activator STAT3 and the repressor STAT3b are co-ex-
pressed in a wide variety of cell types (Fig. 2A), although the
ratio between the two differs between cell types studied. Cell
type-specific differences in the ratio between STAT3 and
STAT3b could lead to differences in the response to IL-5 or
other activators of STAT3. It would therefore be interesting to
determine the mechanism by which the ratio between STAT3
and STAT3b is modulated in a cell type-specific manner. An-
other challenge will be to find physiological processes in which
the ratio between STAT3 and STAT3b is altered in a temporal
or spatial fashion due to signal transduction dependent alter-
native splicing.
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